The strategies of foreign countries or regions for the access and pricing of multi-indication drugs are reviewed to put forward suggestions for the path model of medical insurance access and the calculation method of medical insurance payment standards for multi-indication drugs in China. From overseas experiences，the medical insurance access model includes simultaneous access for all indications and sequential access for a single indication. The medical insurance evaluation model includes pre-admission evaluation and post-admission evaluation. The medical insurance pricing method includes signing a price agreement，setting a weighted average price based on the value of each indication，setting an initial price based on the first indication，and adjusting the price based on budgetary influences. Based on the current medical insurance access system，it needed to further explore and refine the medical insurance access path of multi-indication drugs and the corresponding calculation methods of medical insurance payment standards to promote the refined management of medical insurance.